Evgen Pharma Share News (EVG)

TRADING UPDATES: Coral Products buys Ecodeck; Evgen Pharma recruits

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Evgen starts recruiting volunteers for trial of lead asset

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the start of recruitment for the pharmacokinetic and pharmacodynamic trial in healthy volunteers, and the decision to commence an investigator-sponsored clinical study for the glioblastoma programme on Wednesday.

LONDON MARKET MIDDAY: FTSE 100 trims opening loss amid Fed hike worry

(Alliance News) - European equities traded off session lows heading into Monday afternoon, finding some poise after a poor open, as markets deal with the fallout from last week's US jobs report.

AIM WINNERS & LOSERS: Europa Oil, i3 Energy slide as well disappoints

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Evgen Pharma shares jump 65% as licences SFX-01 composition for autism

(Alliance News) - Evgen Pharma PLC on Monday said it has signed a licencing deal for up to USD160.5 million with Stalicla SA for the global rights to its lead asset SFX-01 in neurodevelopmental disorders and schizophrenia.

UK shareholder meetings calendar - next 7 days

IN BRIEF: Evgen to work with University of Michigan on asset SFX-01

Evgen Pharma PLC- Cheshire, England-based drug development company - Announces collaboration with University of Michigan, to investigate the potential anti-tumour effects of the company's lead asset SFX-01 in colorectal cancer.

Evgen Pharma starts trial to test breast cancer tablet; loss narrows

(Alliance News) - Evgen Pharma PLC on Wednesday said it would begin a trial to test a new medicinal product later this year and said its results for the most recent financial year are in line with expectations.

TRADING UPDATES: Tekcapital fundraise; Kromek wins US government order

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Evgen agrees fresh licensing deal with Spanish institutions

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced a memorandum of understanding with the University of Seville, Consejo Superior de Investigaciones Científicas (CSIC) and Fundación Pública Andaluza Progreso y Salud on behalf of the Institute of Biomedicine of Seville on Tuesday, for second-generation sulforaphane analogues.

Evgen signs agreement for Spanish institutions' sulfoaphane analogues

Evgen signs agreement for Spanish institutions' sulfoaphane analogues

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells